scispace - formally typeset
A

Anders Krifors

Researcher at Karolinska Institutet

Publications -  11
Citations -  39

Anders Krifors is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 3 publications receiving 15 citations. Previous affiliations of Anders Krifors include Uppsala University Hospital & Uppsala University.

Papers
More filters
Journal ArticleDOI

Low rate of COVID-19 seroconversion in health-care workers at a Department of Infectious Diseases in Sweden during the later phase of the first wave; a prospective longitudinal seroepidemiological study.

TL;DR: The low rate of seroconversion during the study suggests that it is possible to prevent transmission of SARS-COV-2 in a high-exposure environment and compliance with adequate infection control guidelines is the likely explanation of the findings.
Journal ArticleDOI

T2Candida Assay in the Diagnosis of Intraabdominal Candidiasis: A Prospective Multicenter Study

TL;DR: T2Candida may be a valuable complement to 1,3-β-D-glucan in the clinical management of high-risk surgical patients because of its rapid results and ease of use.
Journal ArticleDOI

The clinical impact of implementing GenMark ePlex blood culture panels for around-the-clock blood culture identification; a prospective observational study.

TL;DR: The implementation of ePlex is a feasible option to attain around-the-clock blood culture identification in many hospitals and can significantly reduce time-to-pathogen identification and have an impact on clinical decision-making.
Journal ArticleDOI

Long-lasting T-cell response to SARS-CoV-2 antigens after vaccination—a prospective cohort study of HCWs working with COVID-19 patients

TL;DR: In this paper , the authors found that vaccination against SARS-CoV-2 antigens reduces the risk of hospitalisation and death, but vaccine-induced IgG antibodies against the spike protein (IgG S) decline over time, and no correlation was demonstrated between the strength of the T-cell response and time since the second vaccine dose.